Tariffs and MFN Dominate the Headlines, But Details Remain Scant

And the latest pharm-to-table gambit: a $950/month psoriasis drug

Sep 26, 2025

Subscribe to Cost Curve Apex to read the rest.

Upgrade to Apex to get access to this post and other subscriber-only content.

No posts found